Carbohydrate 19.9 Antigen Serum Levels in Liver Disease
Table 1
Baseline characteristics of the study cohort.
Characteristic
Group 1
Group 2
HCV patients ()
HBV patients ()
(%)
(%)
Sex— (%)
Male
74 (63.8)
34 (53.1)
Female
42 (36.2)
30 (46.9)
Age (years)
54 ± 2.3
53 ± 2.6
Race
caucasian
caucasian
Body-mass index (Kg/m2)
26.5 ± 1.0
27.6 ± 1.2
Blood pressure (sys/dia)—mmHg
128 ± 0.8/84 ± 0.3
132 ± 1.1/81 ± 0.7
Weight (Kg)
68.5 ± 1.3
71.2 ± 0.6
AST—IU/L (n.v. 8–18)
63 ± 0.7
73 ± 0.6
ALT—IU/L (n.v. 8–18)
75 ± 1.2
81 ± 0.8
GT—IU/L (n.v. 2–30)
34 ± 1.4
32 ± 1.1
Cholinesterase—IU/L (n.v. 4900–11900)
5982 ± 102.5
5878 ± 190.3
Alkaline Phosphatase—IU/L (n.v. 35–100)
86 ± 0.8
89 ± 1.0
Total bilirubin—mg/dL (n.v. 0.2–1.2)
1.06 ± 0.5
1.07 ± 0.3
Conjugated bilirubin—mg/dL (n.v. 0.0–0.4)
0.16 ± 0. 2
0.14 ± 0.1
Viremia
Mean—log IU/mL
6.40 ± 0.86
6.31 ± 0.92
Genotype
1b (100)
D
39 (81.2)
A
4 (8.3)
D + A
2 (4.2)
D + F
2 (4.2)
D + F + A
1 (2.1)
Fasting glucose—mg/dL (n.v. 74–106)
86 ± 1.3
79 ± 1.5
Serum urea—mg/dL (n.v. 6–40)
42 ± 2.1
39 ± 2.3
Serum creatinin—mg/dL (n.v. 0.7–1.3)
0.7 ± 0.1
0.6 ± 0.2
Serum proteins—mg/dL (n.v. 6–8)
7.1 ± 0.6
7.4 ± 0.3
Fibrinogen—mg/dL (n.v. 200–400)
325 ± 10.3
316 ± 11.5
Prostatic Specific Antigen—ng/mL (n.v. < 0.4)
1.3 ± 0.7
1.8 ± 0.5
ANA, AMA, SMA, LKM1
Negative
Negative
C3-C4—mg/dL
91 ± 1.6
89 ± 1.9
PLTs count-cell/mm3
218 ± 19 × 103
216 ± 21 × 103
Prothrombin time-sec
10 ± 0.3
9.8 ± 0.2
Prothrombin-%
112 ± 0.9
104 ± 1.3
INR—% (n.v. 0.9–1.2)
1.2 ± 0.2
1.1 ± 0.6
Child-Pugh score
≤5
≤5
CA19.9—IU/mL (v.n. < 39)
76.8 ± 42.3
78.8 ± 41.6
Values are expressed as the mean ± SD. The body-mass index is the weight in kilograms divided by the square of the height in meters. Viremia stands for quantitative HCV-RNA in Group 1 and HBV-DNA in Group 2 respectively.
